|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Pre-clinical observation highlighted that triple negative (estrogen receptor/progesterone receptor/human epidermal growth factor receptor)-breast cancer cells displayed resistance to retinoids due to the RARγ high expression profile.
|
29849791 |
2018 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons.
|
8603404 |
1996 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The functional consequence of the interplay between c-Myc oncogene expression and the RARγ to RARα/β balance suggests that prevalence of RARγ over-RARα/β expression levels in breast cancer accompanied by c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARα-isotype-specific agonists and warrant monitoring during clinical trials.
|
22920668 |
2012 |
|
Schizophrenia
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
We detected decreased expression of RARG and NR4A2 mRNAs in females with schizophrenia (p<0.05).
|
27992436 |
2016 |
|
Malignant Childhood Neoplasm
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Collectively, our results defined RARγ as tumor suppressor in colorectal cancer that acts by restricting oncogenic signaling by the Hippo-Yap pathway, with potential implications for new approaches to colorectal cancer therapy.
|
27325643 |
2016 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Modulation of the RARα/β to RARγ expression in mammary glands of normal mice, oncomice, and human mammary cell lines through the alteration of RAR-target gene expression affected cell proliferation, survival and tumor growth.
|
22920668 |
2012 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We, firstly, examined primary NB tumor tissue for a correlation between endogenous RAR gamma expression and clinical stage of the tumor and secondly, the effects of exogenous over-expression of the RAR gamma gene on a human NB tumor cell line.
|
7630632 |
1995 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We recently demonstrated that retinoic acid receptor-γ (RARγ) is overexpressed and acts as a tumor promoter in hepatocellular carcinoma (HCC).
|
28336971 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Differentiation of T1338 was induced by RARα and RARγ isotype-selective retinoids, associated with down-regulation of Sox2, and the failure to induce orthotopic tumors in the brains of SCID mice.
|
25171789 |
2014 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In addition, some genes were up-regulated, including matrix metalloproteinse 2(MMP-2), MMP-16(MT3-MMP), SKY, CD9 and semaphorin V. A number of genes were down-regulated, including neuroendocrine-dlg (NE-dlg), retinoic acid receptor gamma and tumor suppressor DCC colorectal.
|
12174360 |
2002 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Histologic analysis demonstrated that RARγ agonist treatment inhibited cell proliferation activity and stimulated encapsulation of the tumor.
|
31808569 |
2019 |
|
leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.
|
25510432 |
2015 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
The regulation of the subcellular content of CDK1 and RARγ by ATRA is an important process for achieving an effective response in treatment of leukemia.
|
23518499 |
2013 |
|
leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.
|
29530751 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
RARG Gene Dysregulation in Acute Myeloid Leukemia.
|
31709264 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.
|
23518499 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.
|
30996344 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia.
|
20935257 |
2011 |
|
Acute Promyelocytic Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize a novel mechanism of EZH2 function alteration, which may be responsible for an acute myeloid leukemia with APL-like phenotype featuring dysregulation of the RARA and RARG genes.
|
29530751 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
These uncovered fusion genes strongly suggested their contributions to leukemogenesis as driver alternations and APL phenotype may arise by abnormalities of other members of the nuclear receptor superfamily involved in retinoid signaling (RARB or RARG) or even by mechanisms distinct from the formation of aberrant retinoid receptors.
|
30575821 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia.
|
20935257 |
2011 |
|
Acute Promyelocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
RARG fusion is rare but recurrent in APL, further investigation in larger cohorts is expected to assess frequency, clinical characteristics and outcomes of RARG-translocation in APL.
|
30996344 |
2019 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The functional consequence of the interplay between c-Myc oncogene expression and the RARγ to RARα/β balance suggests that prevalence of RARγ over-RARα/β expression levels in breast cancer accompanied by c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARα-isotype-specific agonists and warrant monitoring during clinical trials.
|
22920668 |
2012 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Pre-clinical observation highlighted that triple negative (estrogen receptor/progesterone receptor/human epidermal growth factor receptor)-breast cancer cells displayed resistance to retinoids due to the RARγ high expression profile.
|
29849791 |
2018 |